title: Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
abstract: We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
authors: Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
authors: Jeeyun
authors: J
authors: Ahn
authors: Won Ryang
authors: WR
authors: Wee
authors: Jin Hak
authors: JH
authors: Lee
authors: Joon Young
authors: JY
authors: Hyon
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003315:Cornea / Q000187:drug effects / Q000473:pathology*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D033401:Microscopy, Acoustic; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D014792:Visual Acuity
chemical_list: D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib